Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results - PubMed
3 hours ago
- #leptomeningeal metastasis
- #HER2+ breast cancer
- #systemic therapy
- Study evaluated tucatinib-trastuzumab-capecitabine for HER2+ breast cancer with leptomeningeal metastasis (LM).
- Primary endpoint was overall survival; secondary endpoints included CNS progression-free survival and LM objective response.
- Median overall survival was 10 months, exceeding historical control of 4.4 months.
- 38% of response-evaluable patients achieved composite LM objective response.
- 58% of evaluable patients showed improved neurological deficits.
- Tucatinib reached therapeutic levels in cerebrospinal fluid.
- Study suggests clinical benefit with systemic therapy for HER2+ LM, including extended survival and symptom improvement.